Advertisement
Screener

CARDIFF ONCOLOGY, INC. (CRDF) General and Administrative Expense

2.0 / 5 stars · 44/111 Roast Me

CARDIFF ONCOLOGY, INC. General and Administrative Expense

CARDIFF ONCOLOGY, INC. (CRDF) reported General and Administrative Expense of $11.50 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-26.

Discontinued › Expense Statement › Operating Expenses

us-gaap:GeneralAndAdministrativeExpense · last filed 2018-02-26

  • CARDIFF ONCOLOGY, INC. general and administrative expense for the quarter ending 2017-12-31 was $1.58M, a 30.98% decline year-over-year.
  • CARDIFF ONCOLOGY, INC. general and administrative expense for the quarter ending 2017-09-30 was $3.66M, a 35.00% increase year-over-year.
  • CARDIFF ONCOLOGY, INC. general and administrative expense for the quarter ending 2017-06-30 was $4.06M, a 64.42% increase year-over-year.
  • CARDIFF ONCOLOGY, INC. general and administrative expense for the quarter ending 2017-03-31 was $2.20M, a 45.14% decline year-over-year.
  • CARDIFF ONCOLOGY, INC. general and administrative expense for fiscal 2017 was $11.50M, a 0.19% increase from fiscal 2016.
  • CARDIFF ONCOLOGY, INC. general and administrative expense for fiscal 2016 was $11.48M, a 44.90% increase from fiscal 2015.
  • CARDIFF ONCOLOGY, INC. general and administrative expense for fiscal 2015 was $7.92M, a 36.31% increase from fiscal 2014.
  • CARDIFF ONCOLOGY, INC. general and administrative expense for fiscal 2014 was $5.81M, a 6.18% increase from fiscal 2013.
Period endGeneral and Administrative Expense 3 monthGeneral and Administrative Expense 3 month as first filedGeneral and Administrative Expense 6 monthGeneral and Administrative Expense 6 month as first filedGeneral and Administrative Expense 9 monthGeneral and Administrative Expense 9 month as first filedGeneral and Administrative Expense 12 monthGeneral and Administrative Expense 12 month as first filedGeneral and Administrative Expense 152 monthGeneral and Administrative Expense 155 monthGeneral and Administrative Expense 158 monthGeneral and Administrative Expense 161 monthGeneral and Administrative Expense 164 monthGeneral and Administrative Expense 167 monthGeneral and Administrative Expense 170 monthGeneral and Administrative Expense 176 month
2017-12-31$1.58M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26
$5.24M
derived: sum of 2 quarters · filed 2018-02-26
$9.30M
derived: sum of 3 quarters · filed 2018-02-26
$11.50M
10-K · filed 2018-02-26
2017-09-30$3.66M
10-Q · filed 2017-11-09
$7.72M
derived: sum of 2 quarters · filed 2017-11-09
$9.92M
10-Q · filed 2017-11-09
$12.21M
derived: sum of 4 quarters · filed 2018-02-26
2017-06-30$4.06M
10-Q · filed 2017-08-09
$6.26M
10-Q · filed 2017-08-09
$8.55M
derived: sum of 3 quarters · filed 2018-02-26
$11.26M
derived: sum of 4 quarters · filed 2018-02-26
2017-03-31$2.20M
10-Q · filed 2017-05-10
$4.49M
derived: sum of 2 quarters · filed 2018-02-26
$7.20M
derived: sum of 3 quarters · filed 2018-02-26
$9.67M
derived: sum of 4 quarters · filed 2018-02-26
2016-12-31$2.29M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26
$5.00M
derived: sum of 2 quarters · filed 2018-02-26
$7.47M
derived: sum of 3 quarters · filed 2018-02-26
$11.48M
10-K · filed 2018-02-26
2016-09-30$2.71M
10-Q · filed 2017-11-09
$5.18M
derived: sum of 2 quarters · filed 2017-11-09
$9.18M
10-Q · filed 2017-11-09
$11.35M
derived: sum of 4 quarters · filed 2017-11-09
2016-06-30$2.47M
10-Q · filed 2017-08-09
$6.47M
10-Q · filed 2017-08-09
$8.64M
derived: sum of 3 quarters · filed 2017-08-09
$10.59M
derived: sum of 4 quarters · filed 2017-08-09
2016-03-31$4.00M
10-Q · filed 2017-05-10
$6.17M
derived: sum of 2 quarters · filed 2017-05-10
$8.12M
derived: sum of 3 quarters · filed 2017-05-10
$10.12M
derived: sum of 4 quarters · filed 2017-05-10
2015-12-31$2.16M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15
$4.11M
derived: sum of 2 quarters · filed 2017-03-15
$6.11M
derived: sum of 3 quarters · filed 2017-03-15
$7.92M
10-K · filed 2017-03-15
2015-09-30$1.95M
10-Q · filed 2016-11-09
$3.95M
derived: sum of 2 quarters · filed 2016-11-09
$5.76M
10-Q · filed 2016-11-09
$7.43M
derived: sum of 4 quarters · filed 2017-03-15
2015-06-30$2.00M
10-Q · filed 2016-08-04
$3.81M
10-Q · filed 2016-08-04
$5.48M
derived: sum of 3 quarters · filed 2017-03-15
$6.95M
derived: sum of 4 quarters · filed 2017-03-15
2015-03-31$1.81M
10-Q · filed 2016-05-10
$3.48M
derived: sum of 2 quarters · filed 2017-03-15
$4.95M
derived: sum of 3 quarters · filed 2017-03-15
$6.26M
derived: sum of 4 quarters · filed 2017-03-15
2014-12-31$1.67M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15
$3.14M
derived: sum of 2 quarters · filed 2017-03-15
$4.45M
derived: sum of 3 quarters · filed 2017-03-15
$5.81M
10-K · filed 2017-03-15
2014-09-30$1.47M
10-Q · filed 2015-11-09
$2.78M
derived: sum of 2 quarters · filed 2015-11-09
$4.14M
10-Q · filed 2015-11-09
$5.37M
derived: sum of 4 quarters · filed 2016-03-10
2014-06-30$1.31M
10-Q · filed 2015-08-10
$2.67M
10-Q · filed 2015-08-10
$3.90M
derived: sum of 3 quarters · filed 2016-03-10
$5.78M
derived: sum of 4 quarters · filed 2016-03-10
2014-03-31$1.36M
10-Q · filed 2015-05-05
$2.59M
derived: sum of 2 quarters · filed 2016-03-10
$4.47M
derived: sum of 3 quarters · filed 2016-03-10
$5.48M
derived: sum of 4 quarters · filed 2016-03-10
$32.24M
10-Q · filed 2014-05-12
2013-12-31$1.24M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10
$3.11M
derived: sum of 2 quarters · filed 2016-03-10
$4.13M
derived: sum of 3 quarters · filed 2016-03-10
$5.47M
10-K · filed 2016-03-10
2013-09-30$1.88M
10-Q · filed 2014-11-06
$2.21M
10-Q · filed 2013-11-14
$2.89M
derived: sum of 2 quarters · filed 2014-11-06
$4.24M
10-Q · filed 2014-11-06
$5.39M
10-Q · filed 2013-11-14
$4.73M
derived: sum of 4 quarters · filed 2015-03-12
$31.31M
10-Q · filed 2013-11-14
2013-06-30$1.01M
10-Q · filed 2014-08-07
$1.48M
10-Q · filed 2013-08-14
$2.36M
10-Q · filed 2014-08-07
$3.19M
10-Q · filed 2013-08-14
$2.86M
derived: sum of 3 quarters · filed 2015-03-12
$3.60M
derived: sum of 4 quarters · filed 2015-03-12
$29.11M
10-Q · filed 2013-08-14
2013-03-31$1.35M
10-Q · filed 2014-05-12
$1.71M
10-Q · filed 2013-05-14
$1.84M
derived: sum of 2 quarters · filed 2015-03-12
$2.58M
derived: sum of 3 quarters · filed 2015-03-12
$3.39M
derived: sum of 4 quarters · filed 2015-03-12
$27.63M
10-Q · filed 2013-05-14
2012-12-31$497.06K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12
$1.24M
derived: sum of 2 quarters · filed 2015-03-12
$2.05M
derived: sum of 3 quarters · filed 2015-03-12
$2.87M
10-K · filed 2015-03-12
$3.38M
10-K · filed 2013-04-01
$25.92M
10-K · filed 2013-04-01
2012-09-30$739.04K
10-Q · filed 2013-11-14
$1.55M
derived: sum of 2 quarters · filed 2013-11-14
$2.38M
10-Q · filed 2013-11-14
$2.98M
derived: sum of 4 quarters · filed 2013-11-14
$24.92M
10-Q · filed 2012-11-14
2012-06-30$809.87K
10-Q · filed 2013-08-14
$1.64M
10-Q · filed 2013-08-14
$2.24M
derived: sum of 3 quarters · filed 2013-08-14
$2.83M
derived: sum of 4 quarters · filed 2013-08-14
$24.18M
10-Q · filed 2012-08-14
2012-03-31$826.96K
10-Q · filed 2013-05-14
$1.43M
derived: sum of 2 quarters · filed 2013-05-14
$2.02M
derived: sum of 3 quarters · filed 2013-05-14
$2.60M
derived: sum of 4 quarters · filed 2013-05-14
$23.37M
10-Q · filed 2012-05-15
2011-12-31$602.51K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-04-01
$1.19M
derived: sum of 2 quarters · filed 2013-04-01
$1.77M
derived: sum of 3 quarters · filed 2013-04-01
$2.32M
10-K · filed 2013-04-01
2011-09-30$586.23K
10-Q · filed 2012-11-14
$1.17M
derived: sum of 2 quarters · filed 2012-11-14
$1.72M
10-Q · filed 2012-11-14
2011-06-30$584.02K
10-Q · filed 2012-08-14
$1.14M
10-Q · filed 2012-08-14
2011-03-31$551.04K
10-Q · filed 2012-05-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Black Diamond Therapeutics, Inc. (BDTX)United States$0.109B-2.48
COGNITION THERAPEUTICS INC (CGTX)United States$0.090B-6.52
Pelthos Therapeutics Inc. (PTHS)United States$0.086B-1.20
Atara Biotherapeutics, Inc. (ATRA)United States$0.086B-6.48
LENZ Therapeutics, Inc. (LENZ)United States$0.117B-1.41
Vaxart, Inc. (VXRT)United States$0.080B3.84
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Kalaris Therapeutics, Inc. (KLRS)United States$0.073B-2.19
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B